When designing the topical formulation of the TYK2 inhibitor, we initially referred to the drug concentration of the pan‐JAK inhibitor tofacitinib (2% ointment) used in a phase 2a study for psoriasis,35 and also took into account the solubility of BMS‐986165 in DMSO. Here, TYK2 is linked to psoriasis.